A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT 05384626 Brief Summary Phase 1/2, dose escalation and expansion study designed…
Read more arrow_forwardNCT 05384626 Brief Summary Phase 1/2, dose escalation and expansion study designed…
Read more arrow_forwardNCT 05598151 Brief Summary This is a Phase1 study to assess the…
Read more arrow_forwardNCT 03486873 Brief Summary The purpose of this study is to…
Read more arrow_forwardNCT 06249048 Brief Summary Phase 1/2, Open-label, Multi-center, First-in-human Study of the…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this…
Read more arrow_forward